Willkie represents certain Galil shareholders in the cryotherapy company’s proposed sale.
On May 6, Galil Medical, the global leader in interventional oncology cryoablation technology, announced that it has agreed to be acquired by BTG plc. Willkie represented certain shareholders in connection with the proposed transaction valued at up to $110 million.
Galil Medical delivers innovative cryoablation solutions. The company is addressing patient conditions across multiple physician specialties including conditions affecting bone, kidney, liver, lung and prostate, as well as targeted pain and nerve applications. Its offices are located in Minnesota and Israel. Galil’s shareholders include Thomas, McNerney & Partners, The Vertical Group and Investor Growth Capital.
UK-based BTG is a growing international specialist healthcare company with a portfolio of interventional medicine products to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins, and specialty pharmaceuticals that help patients overexposed to certain medications or toxins.
The deal was handled by partners Gordon Caplan, Sean Ewen and Hillel Jacobson; and law clerk Hugh McLaughlin.